❌

Normal view

There are new articles available, click to refresh the page.
Before yesterdayMain stream

Do ADHD Meds Stunt Growth? A New Stimulant Study Says No

18 September 2026 at 20:30

September 18, 2026

Long-term stimulant use for ADHD negligibly affects adult height, according to a new cohort study published in Pediatric Research that tracked 64,775 children for up to 28 years.1

Parents making ADHD treatment decisions commonly worry that prescription stimulants will stunt their child’s growth. In a 2024 ADDitude survey of 11,000 readers, less than half (42%) of parents chose to medicate their children in the months following an ADHD diagnosis. Those respondents cited side effects like appetite suppression or sleep disruption — both possible impediments to growth — as influences on their decision.

Murky or conflicting findings from previous studies have done little to ease caregivers’ worries.

“Many prior studies either did not follow participants to adult height, so reported effects may reflect delayed maturation rather than true adult height deficits, or they did not account for genetic height potential, which may confound results,” the study’s authors wrote.2, 3

The Pediatric Research study followed a different methodology. It measured the impact of ADHD and stimulant treatment on an individual’s adult height relative to their expected genetic height potential, based on their parents’ heights. Taking an individual-level normalization approach accounted for familial genetic height potential, reducing uncertainty from delayed maturation and group-level bias.

The researchers used health records from a nationwide provider to assemble a retrospective cohort of 17,517 children with treated and untreated ADHD, plus 47,258 in a control group, all born between 1995 and 2003. (Of those with ADHD, 11,846 received stimulant treatment, and 5,671 did not.) They followed the children through 2023 to ensure they reached adult height, defined as at least age 17 for girls and age 19 for boys.

When they compared adult heights across the three groups using an ANOVA (analysis of variance), they found statistically detectable but clinically negligible effect sizes in adult height for girls with ADHD taking stimulant medication and non-significant differences in adult height for boys with ADHD who were treated with stimulants.

“The large sample size increases the likelihood of detecting statistically significant but trivial differences; therefore, effect size analysis is essential for interpreting practical relevance,” the study’s authors wrote.

The effect sizes were consistently very small, and the physical difference measured between the groups was less than a centimeter, which is below the typical range considered clinically meaningful and within the range of routine measurement error.

“Given the very small effect sizes and sub-centimeter absolute differences, clinicians and families can be reassured that decisions regarding stimulant therapy need not be driven primarily by concerns about potential reductions in adult height,” the study’s authors wrote.

Sources

1Gabbay, M., Gabbay, U. and Carmi, D. (2026). The impact of ADHD and neurostimulant treatment on normalized height deviance after accounting for genetic height potential. Pediatric Research. https://doi.org/10.1038/s41390-026-04929-1
2Spencer, T.J. et al. (1996). Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays. J. Am. Acad. Child Adolesc. Psychiatry.  https://doi.org/10.1097/00004583-199611000-00014
3Biederman, J. et al. (2003). Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics. https://doi.org/10.1542/peds.111.5.1010

Centanafadine Receives FDA Approval for the Treatment of ADHD

29 July 2026 at 18:40

July 29, 2026

Centanafadine (brand name: Simtriyo), the first and only norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant has received U.S. Food and Drug Administration (FDA) approval for the treatment of ADHD in adults and pediatric patients aged 6 years and older. The once-daily, extended-release capsule increases the availability of three neurotransmitters involved in ADHD by blocking their reabsorption, according to the drug’s manufacturer, Otsuka.1

The FDA based its approval on the results of four Phase 3 clinical trials that showed centanafadine produced statistically significant and clinically meaningful improvements in ADHD symptoms compared with placebo, as measured by the ADHD Rating Scale–5 (ADHD-RS-5) in children and adolescents and the Adult ADHD Investigator Symptom Rating Scale (AISRS) in adults. Clinical benefits emerged as early as Week One in both pediatric and adult patients.

Simtriyo is expected to become available later this year following scheduling by the U.S. Drug Enforcement Administration (DEA), according to Otsuka.

Results of Phase 3 Clinical Trials

A set of randomized, double-blind, placebo-controlled trials analyzed centanafadine’s efficacy in 480 children and 459 adolescents. Over six weeks, adolescent participants received either high-dose centanafadine (328.8 mg), low-dose centanafadine (164.4 mg), or placebo; children were similarly assigned to a high-dose, low-dose, or placebo group, with doses based on their weight.

About half of the adolescents who received high-dose centanafadine and a third of children in the high-dose centanafadine group demonstrated an 18-point or greater reduction on the ADHD-RS-5 compared with 23% in the placebo group. (Adolescents and children who received low-dose centanafadine did not experience statistically significant improvements.)2, 3

Adults with ADHD also demonstrated statistically significant improvements, according to two randomized trials evaluating sustained-release (SR) centanafadine. A double-blind, placebo-controlled Phase 3 trial involving 859 adults with ADHD between the ages of 18 and 55 randomly assigned participants to high-dose centanafadine (400 mg), low-dose centanafadine (200 mg), or placebo twice daily for six weeks. At the end of the trial, one quarter of adults taking either low- or high-dose centanafadine achieved an 18-point or greater reduction on the AISRS, compared with 15.4% of the placebo group.4

Symptom improvement is sustained with centanafadine, according to a 52-week extension study involving 662 adults. According to the study, AISRS total scores increased up to 57% in adults who used 400 mg centanafadine SR twice daily. The study’s authors concluded that the medication is safe and effective for long-term treatment of adults with ADHD.5

Simtriyo was generally well-tolerated in pediatric and adult patient populations. The most common side effects were rash and decreased appetite in children 6 to 12 years of age; decreased appetite, nausea, rash, headache, and abdominal pain in adolescents 13 to 17 years of age; and headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea in adults.

Potential Future Uses for Centanafadine

The new ADHD medication shows promise for treating co-occurring conditions, as well. A recent eight-week, Phase 3b randomized, double-blind, placebo-controlled trial involving 315 adults (aged 18 to 65 years) with ADHD and generalized or social anxiety disorder found that taking a 280 mg dose of centanafadine once daily significantly improved symptoms of both conditions compared to placebo.5 Otsuka stated that complete results will be presented at a future scientific meeting.

“Centanafadine is another way to get serotonin and was shown to help anxiety and mood in people with ADHD since it kind of has an SSRI built in,” said Greg Mattingly, M.D., during the ADDitude webinar “The Brain Chemistry of ADHD: Understanding Dopamine, Serotonin & Norepinephrine.”

Sources

1Otsuka receives FDA approval for first-in-class SIMTRIYO® (centanafadine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older. Press release. July 24, 2026. Accessed July 24, 2026. https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine

2Ward, C.L., Wilens, T.E., Jin, N., et al. (2025). Efficacy and safety of centanafadine for ADHD treatment in children: A randomized clinical trial. Pediatrics Open Science. https://doi.org/10.1542/pedsos.2024-000349

3Ward, C.L., Childress, A.C., Jin, N., et al (2025). Centanafadine for attention-deficit/hyperactivity disorder in adolescents: A randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2025.06.023

4Adler, L.A., Madera-McDonough, J., et al. (2022). Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001575

5Mattingly, G.W., Turkoglu, O., Chang, D., Ward, C., Skubiak, T., Zhang, Z., Cutler, A.J. (2025). 52-week open-label safety and tolerability study of centanafadine sustained release in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. https://doi.org/10.1097/JCP.0000000000002020

6P3b short-term study of CTN in patients with ADHD and comorbid anxiety. ClinicalTrials.gov. May 6, 2026. Accessed July 1, 2026. https://clinicaltrials.gov/study/NCT06973577

New Insight Into ADHD Stimulants: Optimal Doses by Age, Deprescribing Guidance

25 June 2026 at 14:17

June 25, 2026

Less than one-third of people with ADHD find effective, efficient symptom relief with the first medication they try. According to a 2023 survey, ADDitude readers try 2.6 medications, on average, before settling on one and getting to work finding a dosage ‘sweet spot’ that balances efficacy against side effects. It’s an arduous process of trial-and-error that may benefit from new research on optimal dosing of ADHD medication by patient age.

According to a recent study of more than 25,000 individuals with ADHD aged 5 years and older, the optimal dose of medication varies by drug type and across age groups.1

Published in The Lancet Psychiatry, the systematic review of 164 studies and dose–effect network meta-analysis of 113 double-blind randomized controlled trials identified the most effective dose thresholds for several ADHD medications.

In children and adolescents with ADHD:

  • Methylphenidate (brand name: Ritalin) reached peak efficacy at approximately 45 mg/day.
  • Amphetamines (brand name: Adderall) reached peak efficacy at approximately 25 mg/day.
  • Lisdexamfetamine (brand name: Vyvanse) reached peak efficacy at approximately 55 mg/day.
  • Guanfacine (brand name: Intuniv) reached peak efficacy at approximately 4 mg/day.

In adults with ADHD:

  • Amphetamines reached peak efficacy at approximately 50 mg/day.
  • Methylphenidate efficacy increased without evidence of a plateau.

The U.K. research team, led by Samuele Cortese, M.D., Ph.D., of the National Institute for Health and Care Research (NIHR), found no evidence that exceeding FDA-licensed maximum doses improved any drug’s overall efficacy for any age group. The researchers did acknowledge, however, that some individuals with ADHD do require higher-than-licensed doses of medication.

They also found an association between medication discontinuation and doses at or slightly above peak efficacy. For example, the risk of medication discontinuation increased when amphetamine doses were above 25 mg/day for children and adolescents, and 50 mg/day for adults.

Among adults with ADHD, methylphenidate discontinuation risk increased when doses rose above 50 mg/day. However, taking higher doses of methylphenidate did not increase the likelihood that children or adolescents would stop taking the drug due to side effects.

The researchers emphasized that the study’s results are population-level benchmarks and not prescriptive recommendations.

“Our results are valid at the group level but cannot inform decision-making at the individual level,” they wrote. “Our evidence needs to be complemented by personalized considerations for each patient, with cautious dose titration, as well as implementation of a broader multimodal approach to improve both effectiveness and tolerability of ADHD treatment, ideally in a shared decision-making process.”

If a patient, particularly a child or adolescent, does not experience symptom benefit from an ADHD medication, clinicians are encouraged to titrate up from the minimum dose.

“Evidence from real-world studies shows that a substantial proportion of children and adolescents receive low doses of medication without appropriate upward titration,” the researchers wrote. “This is particularly concerning, as timely and adequate dose adjustment has been associated with improved adherence, probably by facilitating earlier symptom improvement and reinforcing engagement with treatment.”2, 3

Stimulants are considered the first-line treatment for ADHD, but not all children and adults respond to or tolerate stimulant medications; others may prefer to take a non-stimulant. According to the ADDitude treatment survey of more than 11,000 adults and caregivers:

  • 52% of children taking medication for ADHD use methylphenidate, and their caregivers rate it an average of 3.15 out of 5 for efficacy
  • 34% take a form of amphetamine, and their caregivers rated it an average of 2.97 out of 5
  • 16% of children treat their ADHD with non-stimulants, and their caregivers rate it an average of 2.45 out of 5 for efficacy

Among adults taking ADHD medication:

  • 63% use a form of amphetamine, and they rated it an average of 3.31 out of 5 for efficacy
  • 29% use a form of methylphenidate, and they rate it an average of 2.8 out of 5 for efficacy
  • 8% use a non-stimulant, and they rate it an average of 2.3 out of 5 for efficacy

“Gauging whether a medication is working as well as it should, or whether it’s the right medication at all, requires consistent self-appraisal and ongoing communication with your clinician regarding symptom control — or lack thereof,” said William Dodson, M.D., LF-APA, in the ADDitude webinar “Optimizing ADHD Medication: Strategies for Achieving Better Symptom Management.” “It also requires patience as the clinician works to potentially adjust or switch medications before settling on the right combination.”

A new consensus statement developed by the American Society of Clinical Psychopharmacology (ASCP) aims to support clinicians in determining when stimulants are an appropriate treatment and when they should be reconsidered.4

The first-ever formal guidelines identified clinical scenarios for deprescribing stimulant medications in adults with ADHD, including when:

  • A patient is misdiagnosed with ADHD.
  • A patient receives no benefit from the medication.
  • A patient develops tolerance for the medication.
  • Stimulants exacerbate a patient’s co-occurring condition(s).
  • Side effects cannot be managed by reducing the dose of the stimulants.
  • A change in medical status shifts the risk-benefit ratio.
  • A patient persistently exceeds their prescribed dose.
  • A patient diverts their medication to others.
  • A patient uses their medication for enhancement beyond ADHD treatment.

To reach a consensus, at least 75% of the panelists needed to “strongly agree” or “moderately agree” with each statement. The one statement that did not reach a consensus involved cannabis use; 71% of panelists felt that regular cannabis use was an insufficient reason to deprescribe stimulant medication in adults with ADHD.

The guidelines do not provide specific medication tapering schedules, but they do recommend a gradual, personalized taper that emphasizes “sleep hygiene, physical activity, and structured behavioral strategies that support executive functioning.”

Findings from The Lancet Psychiatry study and the consensus statement could inform the forthcoming adult ADHD clinical practice guidelines from the American Professional Society of ADHD and Related Disorders (APSARD), expected later this year.

Sources

1 Nourredine, M., Jurek, L., Hamza, T. et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose–effect network meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/j.euroneuro.2026.112863

2 Olfson, M., Marcus, S., Wan, G. (2009). Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry. https://doi.org/10.1097/CHI.0b013e31818b1c8f

3 Xu, Y., Chung, H., Shu, M., et al. (2023). Dose titration of osmotic release oral system methylphenidate in children and adolescents with attention-deficit hyperactivity disorder: a retrospective cohort study. BMC Pediatr. https://doi.org/10.1186/s12887-023-03850-4

4 Goodman, D., Mago, R., Citrome, L., Swartz, H.A., McIntyre, R.S., et al. (2026). The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2026.112863

Substance Use Disorder Doubles the Risk of ADHD Medication Cessation

20 May 2026 at 21:42

May 21, 2026

Adults with ADHD and a coexisting substance use disorder (SUD) are nearly twice as likely to discontinue treatment with medication compared to their peers with ADHD only, according to a new study published in BMJ Mental Health.1

The Swedish cohort study found that almost half (44%) of adults with ADHD and substance use disorder stopped medication within one year of diagnosis or first SUD-related event, compared to 25% in the ADHD-only group. (The study defined medication discontinuation as a treatment gap of 90 days or more without medication, calculated based on the estimated duration of the previous prescription.) Individuals with a history of abuse of stimulants, cannabis, and/or multiple SUDs experienced significantly higher risks for treatment discontinuation.

Though many patients eventually resumed treatment, those with ADHD and SUD did so at a much lower rate. Notably, individuals with substance-related criminal justice involvement were the least likely to reinitiate ADHD treatment.

“ADHD is often overlooked in prison populations and seldom treated appropriately,” the researchers wrote.2 “Whether this is due to patients experiencing difficulties engaging and adhering to treatment regimens or whether healthcare providers are reluctant to prescribe stimulants to patients with ADHD and SUD in the presence of criminal history, or consider treating this patient group riskier and therefore more often discontinue treatment, is unclear. It is, however, increasingly clear that healthcare services need to be adapted to the specific needs of patients with ADHD, SUD, and criminality to reach more patients and improve long-term outcomes.”3

Though guidelines recommend stimulants as the first-line treatment for ADHD in adults, some clinicians remain wary of using stimulant medication to treat patients with coexisting SUD. Concerns often center on the abuse potential of stimulants; however, ADHD treatment with stimulant medication does not cause future drug misuse or addiction, explained Timothy E. Wilens, M.D., during the ADDitude webinar, “Substance Use Disorder and ADHD: Safe, Effective Treatment Options.”

“In fact, the opposite appears to be true,” Wilens said. “Studies show that early treatment of ADHD and its continued treatment across the lifespan reduce risk for substance use and SUDs.”4

Some clinicians prescribe lower doses of ADHD medication for SUD populations out of caution. However, findings showed lower doses did not improve adherence; higher doses did.

This finding suggests that patients who tolerate stimulants well are more likely to continue treatment, which could prevent criminal behaviors. Patients with ADHD, early onset SUD, and coexisting conduct disorder are at a higher risk for criminality, but those who adhere to their ADHD treatment are better able to avoid it, according to a 2012 population-based Swedish study involving 26,000 adults with ADHD who had criminal convictions. The study, published in the New England Journal of Medicine, found that the crime rate decreased by 32% for men who had taken their ADHD medication. The drop in crime was even bigger for women: 41%.5

A 2025 BMJ study found that ADHD medication use is significantly associated with lower rates of first-time and recurring suicidality, criminal behaviors, vehicular accidents, and substance misuse.6

“This may be because people with multiple occurrences of such events typically have more severe ADHD, making them more likely to benefit from drug treatment,” the study’s authors wrote. “Additionally, the cumulative effect of ADHD drug treatment may lead to additive improvements over time, whereas negative consequences may accumulate the longer an individual goes untreated.”

Factors Influencing Treatment Discontinuation and Reinitiation

The researchers on the BMJ Mental Health study stressed the need to improve medication continuity for individuals with ADHD and SUD. They recommended that treatment providers consider the specific needs of individuals with ADHD and SUD to improve outcomes, especially in young males, who were more likely to discontinue treatment compared to females.

Study results showed those with ADHD and SUD were more likely than those with ADHD only to change providers and medication type between discontinuation and reinitiation of treatment.

“SUD patients, especially those with more severe SUD, have difficulties accessing and engaging with the healthcare system, due to stigma and low health literacy,” the researchers wrote. “Such factors, although impossible to explore using register data, may contribute to the increased risk of treatment discontinuation and lower reinitiation.”

Age also influenced treatment discontinuation and reinitiation. In the ADHD and SUD group, young adults between the ages of 18 and 24 years or younger at the time of their first SUD event were more likely to stop and less likely to restart treatment compared to those with only ADHD.

“Given that treatment adherence has been associated with positive outcomes in both ADHD and SUD, it is important to improve treatment access and continuity of care, especially in the susceptible period during the transition between adolescence and adulthood, a period marked by heightened vulnerability for both SUD onset and for treatment discontinuation,” the researchers wrote.

The study included a total of 55,684 people between the ages of 16 and 26 from Swedish national registers (9,283 people with ADHD and SUD and 46,401 with ADHD only), who had ongoing ADHD medication treatment.

According to Wilens, about one in two adolescents and one in four adults with an SUD has co-occurring ADHD; the risk for SUD is even higher among adolescents and adults with untreated ADHD.7, 8

“Given the known links between ADHD and SUD, adolescents and adults with SUDs or problematic substance use should be screened for ADHD,” he said. “For individuals with both SUDs and ADHD, structured therapies such as cognitive behavioral therapy (CBT) and pharmacological approaches appear most effective. Treatment may start, for example, with CBT that focuses initially on SUD than on the ADHD. Throughout treatment, providers may alternate between focusing on the SUD and ADHD, helping patients understand and identify their thoughts and feelings around substance cravings and urges, and managing symptoms and other ADHD-related issues that may interfere with substance use treatment. Patients also learn how to keep themselves out of high-risk situations.”

Sources

1Capusan AJ, Zhang L, Larsson H, et al. (2026). Discontinuation and reinitiation of pharmacological treatment for ADHD among individuals with ADHD and substance use disorder. BMJ Ment Health. https://mentalhealth.bmj.com/content/29/1/e302138

2Retz, W., Ginsberg, Y., Turner, D., et al. (2021). Attention-deficit/hyperactivity disorder (ADHD), antisociality, and delinquent behavior over the lifespan. Neurosci Biobehav Rev. https://doi.org/10.1016/j.neubiorev.2020.11.025

3Mariani, J.J., Levin, F.R. (2007). Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict. https://doi.org/10.1080/10550490601082783

4Boland, H., DiSalvo, M., Fried, R., Woodworth, K.Y., Wilens, T., Faraone, S.V., & Biederman, J. (2020). A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of psychiatric research. https://doi.org/10.1016/j.jpsychires.2020.01.006

5Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012). Medication for attention deficit-hyperactivity disorder and criminality. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1203241

6Zhang. L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M. et al. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. https://doi.org/10.1136/bmj-2024-083658

7van Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012). Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and alcohol dependence. https://doi.org/10.1016/j.drugalcdep.2011.12.007

8Wilens, T.E., & Morrison, N.R. (2012). Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry. https://doi.org/10.2217/npy.12.39

❌
❌